| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Celiac Disease | 71 | 2021 | 822 | 8.860 |
Why?
|
| Clostridium Infections | 30 | 2023 | 557 | 5.020 |
Why?
|
| Glutens | 24 | 2021 | 240 | 3.880 |
Why?
|
| Enterocolitis, Pseudomembranous | 27 | 2018 | 265 | 3.850 |
Why?
|
| Diet, Gluten-Free | 34 | 2021 | 280 | 3.670 |
Why?
|
| Bacterial Toxins | 38 | 2023 | 931 | 3.350 |
Why?
|
| Enterotoxins | 31 | 2023 | 366 | 3.200 |
Why?
|
| Feces | 13 | 2023 | 1455 | 1.570 |
Why?
|
| Budesonide | 4 | 2020 | 158 | 1.370 |
Why?
|
| Antitoxins | 7 | 2023 | 77 | 1.230 |
Why?
|
| Helicobacter pylori | 11 | 2009 | 377 | 1.210 |
Why?
|
| Diarrhea | 14 | 2023 | 1319 | 1.210 |
Why?
|
| Interleukin-8 | 13 | 2017 | 698 | 1.210 |
Why?
|
| Probiotics | 9 | 2020 | 377 | 1.140 |
Why?
|
| Metronidazole | 8 | 2018 | 231 | 1.110 |
Why?
|
| Intestinal Mucosa | 24 | 2020 | 3022 | 1.080 |
Why?
|
| Saccharomyces | 5 | 2020 | 63 | 1.070 |
Why?
|
| Vancomycin | 7 | 2018 | 503 | 1.050 |
Why?
|
| Bacterial Proteins | 18 | 2020 | 3826 | 1.050 |
Why?
|
| Carrier State | 3 | 2021 | 525 | 1.010 |
Why?
|
| Transglutaminases | 10 | 2020 | 197 | 0.990 |
Why?
|
| Gastrointestinal Agents | 6 | 2019 | 509 | 0.970 |
Why?
|
| Anti-Inflammatory Agents | 6 | 2020 | 1796 | 0.880 |
Why?
|
| Oligopeptides | 6 | 2018 | 1187 | 0.830 |
Why?
|
| Antibodies, Bacterial | 11 | 2016 | 1468 | 0.810 |
Why?
|
| Patient Compliance | 10 | 2017 | 2688 | 0.750 |
Why?
|
| Gastric Mucosa | 8 | 2009 | 599 | 0.660 |
Why?
|
| Colitis | 4 | 2016 | 1229 | 0.640 |
Why?
|
| Immunoglobulin A | 11 | 2023 | 979 | 0.610 |
Why?
|
| Cross Infection | 8 | 2013 | 1434 | 0.600 |
Why?
|
| Anti-Bacterial Agents | 18 | 2023 | 7408 | 0.590 |
Why?
|
| Interleukin-1beta | 2 | 2023 | 998 | 0.590 |
Why?
|
| Food Hypersensitivity | 3 | 2014 | 697 | 0.590 |
Why?
|
| Serologic Tests | 4 | 2015 | 383 | 0.580 |
Why?
|
| HLA-DQ Antigens | 7 | 2018 | 211 | 0.560 |
Why?
|
| Enteritis | 5 | 2007 | 162 | 0.560 |
Why?
|
| IgA Deficiency | 1 | 2016 | 43 | 0.530 |
Why?
|
| Immunoassay | 2 | 2019 | 746 | 0.530 |
Why?
|
| Colon | 9 | 2018 | 1788 | 0.480 |
Why?
|
| Lactobacillus | 2 | 2017 | 204 | 0.480 |
Why?
|
| Antigens, Bacterial | 5 | 2008 | 1155 | 0.470 |
Why?
|
| Recurrence | 16 | 2019 | 8482 | 0.470 |
Why?
|
| Monocytes | 7 | 2004 | 2575 | 0.460 |
Why?
|
| Decision Support Techniques | 2 | 2014 | 2001 | 0.460 |
Why?
|
| Gliadin | 8 | 2017 | 80 | 0.450 |
Why?
|
| Chemokines, CXC | 3 | 2001 | 421 | 0.440 |
Why?
|
| Immunoglobulin G | 14 | 2023 | 4541 | 0.440 |
Why?
|
| Duodenum | 4 | 2017 | 486 | 0.430 |
Why?
|
| Stomach | 2 | 2007 | 694 | 0.390 |
Why?
|
| Humans | 157 | 2023 | 760621 | 0.380 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2013 | 544 | 0.350 |
Why?
|
| Disease Management | 2 | 2020 | 2514 | 0.350 |
Why?
|
| Mesalamine | 1 | 2011 | 136 | 0.350 |
Why?
|
| Intestine, Large | 1 | 2010 | 68 | 0.350 |
Why?
|
| Intestines | 5 | 2018 | 1907 | 0.320 |
Why?
|
| Intestinal Absorption | 1 | 2010 | 400 | 0.310 |
Why?
|
| NF-kappa B | 6 | 2017 | 2488 | 0.310 |
Why?
|
| Epithelial Cells | 7 | 2017 | 3663 | 0.310 |
Why?
|
| Colonic Diseases | 1 | 2010 | 200 | 0.300 |
Why?
|
| Communicable Diseases | 3 | 2021 | 878 | 0.300 |
Why?
|
| Helicobacter Infections | 5 | 2009 | 386 | 0.290 |
Why?
|
| Receptor, PAR-2 | 1 | 2007 | 33 | 0.290 |
Why?
|
| Female | 80 | 2021 | 391270 | 0.290 |
Why?
|
| Adult | 57 | 2021 | 219994 | 0.290 |
Why?
|
| Up-Regulation | 6 | 2008 | 4122 | 0.290 |
Why?
|
| Transcriptional Activation | 2 | 2005 | 1755 | 0.290 |
Why?
|
| Mitogen-Activated Protein Kinases | 4 | 2001 | 1246 | 0.290 |
Why?
|
| Severity of Illness Index | 11 | 2020 | 15840 | 0.270 |
Why?
|
| Immunization | 6 | 2020 | 1227 | 0.270 |
Why?
|
| Transcription, Genetic | 5 | 2001 | 7593 | 0.270 |
Why?
|
| Colitis, Microscopic | 1 | 2007 | 72 | 0.260 |
Why?
|
| Guideline Adherence | 1 | 2016 | 2283 | 0.260 |
Why?
|
| Adaptive Immunity | 1 | 2011 | 726 | 0.260 |
Why?
|
| Colitis, Ulcerative | 3 | 2020 | 1919 | 0.260 |
Why?
|
| Salivary Proline-Rich Proteins | 2 | 2015 | 5 | 0.260 |
Why?
|
| Male | 78 | 2021 | 359744 | 0.260 |
Why?
|
| Middle Aged | 55 | 2021 | 220352 | 0.260 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 4 | 2013 | 474 | 0.260 |
Why?
|
| Bacterial Vaccines | 2 | 2018 | 401 | 0.250 |
Why?
|
| Autoantibodies | 7 | 2020 | 2118 | 0.240 |
Why?
|
| Intestine, Small | 6 | 2019 | 1207 | 0.230 |
Why?
|
| Antibodies, Neutralizing | 4 | 2018 | 1933 | 0.220 |
Why?
|
| Placebo Effect | 1 | 2007 | 520 | 0.220 |
Why?
|
| Ileum | 6 | 2012 | 555 | 0.220 |
Why?
|
| Immunoglobulin A, Secretory | 2 | 2001 | 104 | 0.210 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 12 | 2014 | 3804 | 0.210 |
Why?
|
| GTP-Binding Proteins | 6 | 2020 | 951 | 0.210 |
Why?
|
| Genetic Testing | 2 | 2015 | 3531 | 0.210 |
Why?
|
| Tight Junctions | 3 | 2014 | 315 | 0.210 |
Why?
|
| Tablets, Enteric-Coated | 2 | 2019 | 22 | 0.200 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2013 | 3484 | 0.200 |
Why?
|
| Risk Factors | 20 | 2020 | 74359 | 0.200 |
Why?
|
| Aged | 36 | 2020 | 169152 | 0.200 |
Why?
|
| Antibodies, Monoclonal | 4 | 2018 | 9185 | 0.200 |
Why?
|
| Sigmoid Neoplasms | 1 | 2002 | 54 | 0.200 |
Why?
|
| Verapamil | 1 | 2002 | 242 | 0.190 |
Why?
|
| Endoscopy, Gastrointestinal | 4 | 2010 | 867 | 0.190 |
Why?
|
| Diagnosis, Differential | 5 | 2021 | 12965 | 0.190 |
Why?
|
| Sp1 Transcription Factor | 1 | 2001 | 140 | 0.190 |
Why?
|
| Interleukin-16 | 1 | 2000 | 34 | 0.190 |
Why?
|
| Combined Modality Therapy | 5 | 2019 | 8552 | 0.180 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2011 | 2282 | 0.180 |
Why?
|
| Cell Line | 14 | 2018 | 15620 | 0.180 |
Why?
|
| Aged, 80 and over | 19 | 2019 | 58995 | 0.180 |
Why?
|
| Young Adult | 22 | 2020 | 58741 | 0.170 |
Why?
|
| Critical Care | 1 | 2013 | 2699 | 0.170 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2001 | 151 | 0.170 |
Why?
|
| Crohn Disease | 4 | 2020 | 2275 | 0.170 |
Why?
|
| Gastrointestinal Transit | 2 | 1999 | 99 | 0.170 |
Why?
|
| Administration, Oral | 6 | 2019 | 4035 | 0.170 |
Why?
|
| Antibodies | 5 | 2015 | 2421 | 0.170 |
Why?
|
| Potassium Deficiency | 1 | 1999 | 10 | 0.170 |
Why?
|
| Autoimmune Diseases | 2 | 2009 | 2250 | 0.170 |
Why?
|
| Data Collection | 1 | 2009 | 3315 | 0.170 |
Why?
|
| Cecum | 2 | 2018 | 232 | 0.170 |
Why?
|
| Cyclosporine | 1 | 2002 | 777 | 0.170 |
Why?
|
| Retrospective Studies | 17 | 2021 | 80372 | 0.160 |
Why?
|
| I-kappa B Proteins | 1 | 1999 | 212 | 0.160 |
Why?
|
| Calcium Channel Blockers | 1 | 2002 | 694 | 0.160 |
Why?
|
| Host-Pathogen Interactions | 1 | 2007 | 1447 | 0.160 |
Why?
|
| Animals | 39 | 2021 | 167963 | 0.150 |
Why?
|
| Digestive System | 1 | 1999 | 244 | 0.150 |
Why?
|
| Flagellin | 1 | 2018 | 124 | 0.150 |
Why?
|
| Prevalence | 9 | 2020 | 15687 | 0.150 |
Why?
|
| Gene Expression Regulation | 4 | 2013 | 11903 | 0.150 |
Why?
|
| Microbiological Techniques | 1 | 2018 | 98 | 0.150 |
Why?
|
| Biopsy, Needle | 3 | 2011 | 1630 | 0.150 |
Why?
|
| Immunoglobulins, Intravenous | 3 | 2001 | 664 | 0.140 |
Why?
|
| Health Status | 2 | 2014 | 4081 | 0.140 |
Why?
|
| Biopsy | 6 | 2021 | 6771 | 0.140 |
Why?
|
| Phosphorylation | 6 | 2017 | 8313 | 0.140 |
Why?
|
| Aminoglycosides | 1 | 2017 | 163 | 0.140 |
Why?
|
| Treatment Outcome | 11 | 2019 | 65017 | 0.140 |
Why?
|
| Neutrophil Activation | 1 | 1997 | 181 | 0.140 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2018 | 256 | 0.140 |
Why?
|
| Colonic Polyps | 1 | 2002 | 551 | 0.140 |
Why?
|
| Feeding Behavior | 1 | 2009 | 3185 | 0.140 |
Why?
|
| Secondary Prevention | 3 | 2018 | 1548 | 0.140 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2013 | 478 | 0.130 |
Why?
|
| Depressive Disorder | 1 | 2009 | 3726 | 0.130 |
Why?
|
| Chemokine CCL2 | 1 | 1998 | 605 | 0.130 |
Why?
|
| Glucocorticoids | 2 | 2019 | 2145 | 0.130 |
Why?
|
| Vaccines, Synthetic | 1 | 2018 | 617 | 0.130 |
Why?
|
| Caspases | 1 | 1999 | 878 | 0.130 |
Why?
|
| Urease | 3 | 2009 | 39 | 0.130 |
Why?
|
| Delayed Diagnosis | 1 | 2020 | 464 | 0.130 |
Why?
|
| Toxemia | 1 | 2015 | 14 | 0.130 |
Why?
|
| Chemokine CXCL5 | 3 | 2001 | 28 | 0.130 |
Why?
|
| Endopeptidases | 3 | 2014 | 772 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2020 | 10827 | 0.120 |
Why?
|
| Women's Health | 1 | 2005 | 2056 | 0.120 |
Why?
|
| Ilium | 1 | 1996 | 154 | 0.120 |
Why?
|
| Salivary Proteins and Peptides | 1 | 2015 | 48 | 0.120 |
Why?
|
| Incidence | 5 | 2015 | 21392 | 0.120 |
Why?
|
| Enzyme Activation | 5 | 2001 | 3602 | 0.120 |
Why?
|
| Saliva | 2 | 2017 | 820 | 0.120 |
Why?
|
| Predictive Value of Tests | 7 | 2015 | 15289 | 0.120 |
Why?
|
| Lipopolysaccharides | 2 | 2001 | 2209 | 0.120 |
Why?
|
| Sensitivity and Specificity | 6 | 2019 | 14660 | 0.120 |
Why?
|
| Immunologic Factors | 2 | 2021 | 1588 | 0.120 |
Why?
|
| RNA, Messenger | 9 | 2007 | 12766 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 4 | 2015 | 6068 | 0.120 |
Why?
|
| Neutrophils | 4 | 2000 | 3767 | 0.120 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2016 | 296 | 0.120 |
Why?
|
| MAP Kinase Signaling System | 2 | 2004 | 1484 | 0.110 |
Why?
|
| Atrophy | 3 | 2017 | 1627 | 0.110 |
Why?
|
| Aspartate Aminotransferases | 1 | 2015 | 416 | 0.110 |
Why?
|
| Inflammation | 5 | 2018 | 10756 | 0.110 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 2 | 2013 | 144 | 0.110 |
Why?
|
| Genome, Bacterial | 1 | 2018 | 770 | 0.110 |
Why?
|
| Spores, Bacterial | 1 | 2013 | 114 | 0.110 |
Why?
|
| Oxazolidinones | 1 | 2013 | 97 | 0.110 |
Why?
|
| Adolescent | 13 | 2019 | 87810 | 0.110 |
Why?
|
| Trypsin Inhibitors | 1 | 2012 | 36 | 0.110 |
Why?
|
| Europe | 2 | 2011 | 3441 | 0.110 |
Why?
|
| Sodium Dodecyl Sulfate | 1 | 2013 | 127 | 0.110 |
Why?
|
| Lactulose | 1 | 2012 | 31 | 0.110 |
Why?
|
| Phospholipase C gamma | 1 | 2013 | 130 | 0.110 |
Why?
|
| Inflammatory Bowel Diseases | 4 | 2016 | 2421 | 0.110 |
Why?
|
| Plant Proteins | 2 | 2012 | 370 | 0.110 |
Why?
|
| Biological Therapy | 1 | 2014 | 139 | 0.110 |
Why?
|
| Triticum | 1 | 2012 | 89 | 0.100 |
Why?
|
| Mice | 16 | 2021 | 81208 | 0.100 |
Why?
|
| Alanine Transaminase | 1 | 2015 | 606 | 0.100 |
Why?
|
| Cathelicidins | 1 | 2012 | 81 | 0.100 |
Why?
|
| Prognosis | 9 | 2017 | 29658 | 0.100 |
Why?
|
| Drug Administration Schedule | 1 | 2020 | 4899 | 0.100 |
Why?
|
| Esophagitis | 1 | 2013 | 163 | 0.100 |
Why?
|
| Early Diagnosis | 2 | 2016 | 1180 | 0.100 |
Why?
|
| Prospective Studies | 11 | 2021 | 54303 | 0.100 |
Why?
|
| Genetic Markers | 2 | 2015 | 2608 | 0.090 |
Why?
|
| Caco-2 Cells | 2 | 2002 | 368 | 0.090 |
Why?
|
| Medical Records | 1 | 2016 | 1407 | 0.090 |
Why?
|
| Case-Control Studies | 9 | 2020 | 22053 | 0.090 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2012 | 580 | 0.090 |
Why?
|
| Likelihood Functions | 1 | 2014 | 987 | 0.090 |
Why?
|
| Point-of-Care Systems | 1 | 2019 | 1204 | 0.090 |
Why?
|
| Continuity of Patient Care | 1 | 2017 | 1066 | 0.090 |
Why?
|
| Rehabilitation Centers | 1 | 2012 | 248 | 0.090 |
Why?
|
| North America | 2 | 2015 | 1284 | 0.090 |
Why?
|
| Interleukin-1 | 3 | 1999 | 1249 | 0.090 |
Why?
|
| Quality of Life | 3 | 2020 | 13308 | 0.090 |
Why?
|
| Gastric Mucins | 1 | 2009 | 19 | 0.090 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2018 | 3735 | 0.090 |
Why?
|
| Drug Therapy, Combination | 2 | 2017 | 6498 | 0.080 |
Why?
|
| Food Services | 1 | 2012 | 205 | 0.080 |
Why?
|
| Body Mass Index | 2 | 2021 | 12914 | 0.080 |
Why?
|
| Immunity, Mucosal | 2 | 2007 | 482 | 0.080 |
Why?
|
| Mice, Nude | 2 | 2013 | 3607 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2002 | 4166 | 0.080 |
Why?
|
| DNA Fingerprinting | 1 | 2009 | 111 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2021 | 3696 | 0.080 |
Why?
|
| Adenoviridae | 1 | 2013 | 1084 | 0.080 |
Why?
|
| Algorithms | 4 | 2014 | 13981 | 0.080 |
Why?
|
| Gastrointestinal Hormones | 1 | 1989 | 101 | 0.080 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 39261 | 0.080 |
Why?
|
| Infusions, Intravenous | 2 | 2017 | 2234 | 0.080 |
Why?
|
| Parturition | 1 | 2012 | 446 | 0.080 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2015 | 1827 | 0.080 |
Why?
|
| Bacterial Typing Techniques | 1 | 2009 | 260 | 0.080 |
Why?
|
| Lymphocytes | 1 | 2016 | 2611 | 0.080 |
Why?
|
| Double-Blind Method | 5 | 2017 | 12427 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2021 | 17790 | 0.080 |
Why?
|
| Gastrointestinal Diseases | 2 | 2020 | 1190 | 0.080 |
Why?
|
| Suloctidil | 1 | 1987 | 2 | 0.080 |
Why?
|
| Cytokines | 3 | 2018 | 7343 | 0.080 |
Why?
|
| Receptors, Cell Surface | 3 | 2004 | 2825 | 0.080 |
Why?
|
| Drug Discovery | 1 | 2016 | 1057 | 0.080 |
Why?
|
| Flow Cytometry | 1 | 2018 | 5870 | 0.070 |
Why?
|
| Societies | 2 | 2018 | 108 | 0.070 |
Why?
|
| Focus Groups | 2 | 2012 | 1378 | 0.070 |
Why?
|
| Perception | 1 | 2014 | 1195 | 0.070 |
Why?
|
| Colonic Neoplasms | 3 | 2010 | 2526 | 0.070 |
Why?
|
| Erythema | 1 | 1989 | 262 | 0.070 |
Why?
|
| Permeability | 3 | 2020 | 719 | 0.070 |
Why?
|
| Glucagon-Like Peptides | 1 | 1989 | 159 | 0.070 |
Why?
|
| United States | 8 | 2021 | 72461 | 0.070 |
Why?
|
| Mucus | 1 | 2009 | 342 | 0.070 |
Why?
|
| Cattle | 3 | 1999 | 3847 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 6 | 2020 | 4357 | 0.070 |
Why?
|
| Universities | 1 | 2012 | 992 | 0.070 |
Why?
|
| International Classification of Diseases | 1 | 2013 | 894 | 0.070 |
Why?
|
| Lymphopenia | 1 | 2009 | 280 | 0.070 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2008 | 278 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 2803 | 0.070 |
Why?
|
| Propanolamines | 1 | 1987 | 162 | 0.070 |
Why?
|
| Half-Life | 1 | 2008 | 652 | 0.070 |
Why?
|
| Adjuvants, Immunologic | 2 | 2002 | 1039 | 0.070 |
Why?
|
| Rabbits | 6 | 1998 | 4773 | 0.070 |
Why?
|
| Gastroparesis | 1 | 2009 | 137 | 0.070 |
Why?
|
| DNA-Binding Proteins | 2 | 2001 | 9585 | 0.070 |
Why?
|
| Raynaud Disease | 1 | 1987 | 79 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2007 | 4573 | 0.070 |
Why?
|
| Gastric Emptying | 1 | 2009 | 243 | 0.070 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2008 | 356 | 0.070 |
Why?
|
| Osteoporosis | 1 | 2016 | 1600 | 0.070 |
Why?
|
| Irritable Bowel Syndrome | 2 | 2014 | 453 | 0.070 |
Why?
|
| Cefotaxime | 1 | 1986 | 35 | 0.070 |
Why?
|
| Self Report | 1 | 2017 | 3711 | 0.070 |
Why?
|
| Phototherapy | 1 | 2009 | 368 | 0.070 |
Why?
|
| Immunophenotyping | 1 | 2011 | 1871 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2020 | 10344 | 0.070 |
Why?
|
| Proton Pump Inhibitors | 2 | 2013 | 551 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2018 | 4490 | 0.060 |
Why?
|
| Blotting, Western | 2 | 2018 | 5039 | 0.060 |
Why?
|
| Biomedical Research | 1 | 2021 | 3426 | 0.060 |
Why?
|
| Pyridines | 2 | 2013 | 2879 | 0.060 |
Why?
|
| Luciferases, Bacterial | 1 | 2005 | 6 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 7 | 2018 | 22023 | 0.060 |
Why?
|
| Macrophage-1 Antigen | 2 | 1997 | 286 | 0.060 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2013 | 1613 | 0.060 |
Why?
|
| T-Lymphocytes | 2 | 2002 | 10181 | 0.060 |
Why?
|
| Testosterone | 1 | 2016 | 2470 | 0.060 |
Why?
|
| Histamine H2 Antagonists | 1 | 2006 | 167 | 0.060 |
Why?
|
| Culture Media, Conditioned | 2 | 1997 | 522 | 0.060 |
Why?
|
| Signal Transduction | 6 | 2018 | 23376 | 0.060 |
Why?
|
| Child | 10 | 2021 | 79806 | 0.060 |
Why?
|
| Glycosylation | 2 | 2015 | 1096 | 0.060 |
Why?
|
| Bulimia | 1 | 2007 | 399 | 0.060 |
Why?
|
| Terminology as Topic | 1 | 2012 | 1535 | 0.060 |
Why?
|
| Cytotoxins | 1 | 2005 | 153 | 0.060 |
Why?
|
| src-Family Kinases | 1 | 2007 | 535 | 0.060 |
Why?
|
| Histocompatibility Testing | 1 | 2006 | 717 | 0.060 |
Why?
|
| Hypersensitivity, Immediate | 1 | 1987 | 345 | 0.060 |
Why?
|
| Cost of Illness | 1 | 2014 | 1940 | 0.060 |
Why?
|
| Hospital Costs | 1 | 2010 | 976 | 0.060 |
Why?
|
| Random Allocation | 1 | 2009 | 2394 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2007 | 2648 | 0.060 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2018 | 1006 | 0.060 |
Why?
|
| False Negative Reactions | 2 | 2015 | 573 | 0.060 |
Why?
|
| Genetic Vectors | 1 | 2013 | 3380 | 0.050 |
Why?
|
| Phenotype | 3 | 2020 | 16546 | 0.050 |
Why?
|
| RNA, Bacterial | 1 | 2005 | 385 | 0.050 |
Why?
|
| Cricetinae | 3 | 2016 | 2427 | 0.050 |
Why?
|
| Escherichia coli Vaccines | 1 | 2002 | 10 | 0.050 |
Why?
|
| Luciferases | 2 | 2001 | 716 | 0.050 |
Why?
|
| Virulence | 1 | 2007 | 1298 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2009 | 4353 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 3 | 2001 | 6131 | 0.050 |
Why?
|
| Infant | 4 | 2020 | 36060 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2007 | 2471 | 0.050 |
Why?
|
| Headache | 1 | 2011 | 1249 | 0.050 |
Why?
|
| Infection Control | 1 | 2010 | 983 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 1 | 2013 | 2640 | 0.050 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 1997 | 1126 | 0.050 |
Why?
|
| Pyrazoles | 1 | 2013 | 1999 | 0.050 |
Why?
|
| Outpatients | 1 | 2010 | 1607 | 0.050 |
Why?
|
| Clinical Trials as Topic | 2 | 2019 | 8056 | 0.050 |
Why?
|
| Community-Acquired Infections | 1 | 2006 | 461 | 0.050 |
Why?
|
| Prolapse | 1 | 2002 | 63 | 0.050 |
Why?
|
| Steroids | 2 | 2010 | 928 | 0.050 |
Why?
|
| Peptides | 1 | 2014 | 4354 | 0.050 |
Why?
|
| Tyrphostins | 1 | 2001 | 63 | 0.050 |
Why?
|
| Models, Theoretical | 1 | 2014 | 3562 | 0.050 |
Why?
|
| Anion Exchange Resins | 1 | 2001 | 10 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 2 | 2001 | 6216 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2001 | 12103 | 0.050 |
Why?
|
| Remission Induction | 1 | 2007 | 2392 | 0.050 |
Why?
|
| Monokines | 2 | 1998 | 71 | 0.050 |
Why?
|
| Purinergic P2 Receptor Agonists | 1 | 2001 | 13 | 0.050 |
Why?
|
| Colonoscopy | 1 | 2010 | 1387 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2016 | 5075 | 0.050 |
Why?
|
| Probability | 1 | 2007 | 2475 | 0.050 |
Why?
|
| Neurotensin | 1 | 2001 | 57 | 0.050 |
Why?
|
| Uridine Diphosphate | 1 | 2001 | 33 | 0.050 |
Why?
|
| Sigmoidoscopy | 1 | 2002 | 150 | 0.050 |
Why?
|
| Fertility | 1 | 2006 | 773 | 0.050 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2004 | 446 | 0.050 |
Why?
|
| DNA, Bacterial | 2 | 2018 | 1456 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2016 | 8035 | 0.050 |
Why?
|
| Trinitrobenzenesulfonic Acid | 1 | 2000 | 64 | 0.050 |
Why?
|
| Biochemistry | 1 | 2001 | 114 | 0.050 |
Why?
|
| Cohort Studies | 3 | 2020 | 41335 | 0.050 |
Why?
|
| Autoantigens | 1 | 2005 | 877 | 0.050 |
Why?
|
| Hematologic Tests | 1 | 2001 | 238 | 0.050 |
Why?
|
| Genes, Reporter | 2 | 2001 | 1529 | 0.050 |
Why?
|
| Necrosis | 2 | 1999 | 1612 | 0.040 |
Why?
|
| Logistic Models | 2 | 2009 | 13314 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2000 | 74 | 0.040 |
Why?
|
| Laxatives | 1 | 2020 | 90 | 0.040 |
Why?
|
| Norway | 1 | 2021 | 496 | 0.040 |
Why?
|
| Disease Outbreaks | 2 | 1987 | 1758 | 0.040 |
Why?
|
| Amino Acid Sequence | 4 | 2015 | 13451 | 0.040 |
Why?
|
| Receptors, Immunologic | 2 | 1998 | 1411 | 0.040 |
Why?
|
| Professional-Patient Relations | 1 | 2005 | 726 | 0.040 |
Why?
|
| Immunity, Innate | 2 | 2012 | 3047 | 0.040 |
Why?
|
| Age Factors | 3 | 2018 | 18416 | 0.040 |
Why?
|
| Colony Count, Microbial | 1 | 2000 | 328 | 0.040 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 1999 | 68 | 0.040 |
Why?
|
| Pancrelipase | 1 | 2018 | 7 | 0.040 |
Why?
|
| Food Contamination | 1 | 2020 | 192 | 0.040 |
Why?
|
| Immunohistochemistry | 3 | 2002 | 11071 | 0.040 |
Why?
|
| Malnutrition | 2 | 2020 | 640 | 0.040 |
Why?
|
| Rhodobacter sphaeroides | 1 | 1998 | 13 | 0.040 |
Why?
|
| Colostrum | 1 | 1999 | 28 | 0.040 |
Why?
|
| Neutralization Tests | 2 | 2014 | 728 | 0.040 |
Why?
|
| Lactococcus lactis | 1 | 2018 | 29 | 0.040 |
Why?
|
| Disease Models, Animal | 5 | 2015 | 18137 | 0.040 |
Why?
|
| Genotype | 2 | 2014 | 12960 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2009 | 2502 | 0.040 |
Why?
|
| Lipid A | 1 | 1998 | 70 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 2 | 2015 | 5508 | 0.040 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 1999 | 189 | 0.040 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2000 | 277 | 0.040 |
Why?
|
| Monitoring, Physiologic | 1 | 2006 | 1784 | 0.040 |
Why?
|
| Diet | 2 | 2014 | 8010 | 0.040 |
Why?
|
| Microvilli | 3 | 1996 | 233 | 0.040 |
Why?
|
| Nutrition Surveys | 2 | 2016 | 1725 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 1 | 2008 | 2696 | 0.040 |
Why?
|
| Length of Stay | 1 | 2012 | 6479 | 0.040 |
Why?
|
| Hospitalization | 3 | 2010 | 10790 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2005 | 2913 | 0.040 |
Why?
|
| Infectious Disease Medicine | 1 | 2018 | 49 | 0.040 |
Why?
|
| Chemotactic Factors | 1 | 1998 | 196 | 0.040 |
Why?
|
| Anorexia Nervosa | 1 | 2007 | 1361 | 0.040 |
Why?
|
| Exotoxins | 1 | 1998 | 121 | 0.040 |
Why?
|
| Societies, Medical | 2 | 2021 | 3905 | 0.040 |
Why?
|
| Sex Factors | 2 | 2013 | 10547 | 0.040 |
Why?
|
| Mouth Diseases | 1 | 2020 | 238 | 0.040 |
Why?
|
| Neutrophil Infiltration | 1 | 2000 | 393 | 0.040 |
Why?
|
| Interleukin-11 | 1 | 1997 | 59 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2009 | 3455 | 0.040 |
Why?
|
| Glucosyltransferases | 1 | 2017 | 96 | 0.040 |
Why?
|
| Immune Sera | 1 | 1997 | 613 | 0.040 |
Why?
|
| Ileitis | 1 | 1997 | 39 | 0.040 |
Why?
|
| Zinc | 1 | 2001 | 689 | 0.040 |
Why?
|
| Critical Illness | 1 | 2010 | 2709 | 0.040 |
Why?
|
| Pepsin A | 1 | 1997 | 66 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2021 | 699 | 0.040 |
Why?
|
| Sucrase-Isomaltase Complex | 1 | 1996 | 12 | 0.040 |
Why?
|
| Genes, MHC Class I | 1 | 1997 | 240 | 0.040 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2000 | 687 | 0.030 |
Why?
|
| Gastric Acid | 1 | 1997 | 98 | 0.030 |
Why?
|
| Interleukin-5 | 1 | 2017 | 268 | 0.030 |
Why?
|
| Survival Rate | 1 | 2011 | 12808 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2017 | 818 | 0.030 |
Why?
|
| Bacterial Load | 1 | 2017 | 151 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2013 | 5643 | 0.030 |
Why?
|
| Flavonoids | 1 | 1999 | 445 | 0.030 |
Why?
|
| Registries | 2 | 2016 | 8469 | 0.030 |
Why?
|
| Plant Lectins | 1 | 1996 | 103 | 0.030 |
Why?
|
| Diagnostic Techniques, Digestive System | 1 | 2016 | 46 | 0.030 |
Why?
|
| Antibody Formation | 1 | 2001 | 1400 | 0.030 |
Why?
|
| Substance P | 1 | 1997 | 333 | 0.030 |
Why?
|
| Mice, Knockout | 3 | 2018 | 14372 | 0.030 |
Why?
|
| Hydrolysis | 1 | 2017 | 665 | 0.030 |
Why?
|
| Integrins | 1 | 2000 | 839 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 422 | 0.030 |
Why?
|
| Membrane Potentials | 1 | 1999 | 1095 | 0.030 |
Why?
|
| Peptide Hydrolases | 1 | 2018 | 623 | 0.030 |
Why?
|
| Cross Reactions | 2 | 2015 | 818 | 0.030 |
Why?
|
| Escherichia coli Proteins | 1 | 2002 | 1066 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2009 | 12159 | 0.030 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2001 | 1130 | 0.030 |
Why?
|
| Sequence Homology | 1 | 2015 | 195 | 0.030 |
Why?
|
| Patient Advocacy | 1 | 2017 | 358 | 0.030 |
Why?
|
| Peroxidase | 1 | 2018 | 605 | 0.030 |
Why?
|
| Binding Sites | 2 | 2001 | 6048 | 0.030 |
Why?
|
| Quinazolines | 1 | 2001 | 1363 | 0.030 |
Why?
|
| Rats, Wistar | 5 | 1997 | 1850 | 0.030 |
Why?
|
| Immune System | 1 | 2000 | 798 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2009 | 3527 | 0.030 |
Why?
|
| Potassium | 1 | 1999 | 1313 | 0.030 |
Why?
|
| Drug Resistance, Microbial | 1 | 1998 | 856 | 0.030 |
Why?
|
| Mesocricetus | 1 | 2014 | 252 | 0.030 |
Why?
|
| Parotid Gland | 1 | 2015 | 175 | 0.030 |
Why?
|
| Gene Expression Profiling | 2 | 2008 | 9411 | 0.030 |
Why?
|
| Ganglia, Spinal | 1 | 1997 | 523 | 0.030 |
Why?
|
| Blood Preservation | 1 | 2015 | 168 | 0.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2013 | 5251 | 0.030 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2019 | 643 | 0.030 |
Why?
|
| Eye Diseases | 1 | 2020 | 651 | 0.030 |
Why?
|
| Vero Cells | 1 | 2015 | 482 | 0.030 |
Why?
|
| Risk | 1 | 2006 | 9631 | 0.030 |
Why?
|
| Canada | 1 | 2019 | 2128 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2016 | 780 | 0.030 |
Why?
|
| Drosophila | 1 | 2001 | 1492 | 0.030 |
Why?
|
| Time Factors | 5 | 2015 | 40165 | 0.030 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2015 | 242 | 0.030 |
Why?
|
| Ketotifen | 1 | 1993 | 23 | 0.030 |
Why?
|
| Binding Sites, Antibody | 1 | 2014 | 337 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 2001 | 981 | 0.030 |
Why?
|
| Musculoskeletal Diseases | 1 | 2020 | 595 | 0.030 |
Why?
|
| Liver Function Tests | 1 | 2015 | 524 | 0.030 |
Why?
|
| Eating | 1 | 2020 | 1539 | 0.030 |
Why?
|
| Diverticulitis, Colonic | 1 | 2015 | 138 | 0.030 |
Why?
|
| Imidazoles | 1 | 1999 | 1180 | 0.030 |
Why?
|
| Antibody Specificity | 1 | 2015 | 1060 | 0.030 |
Why?
|
| Delivery of Health Care | 2 | 2021 | 5325 | 0.030 |
Why?
|
| Lymphocytosis | 1 | 2014 | 119 | 0.030 |
Why?
|
| Ileal Diseases | 1 | 1993 | 69 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 2 | 2001 | 5785 | 0.030 |
Why?
|
| Hordeum | 1 | 2012 | 18 | 0.030 |
Why?
|
| Protein Stability | 1 | 2015 | 566 | 0.030 |
Why?
|
| Molecular Sequence Data | 3 | 2015 | 17624 | 0.030 |
Why?
|
| Bone Density | 1 | 2006 | 3534 | 0.030 |
Why?
|
| Blotting, Northern | 1 | 1994 | 1543 | 0.030 |
Why?
|
| Rats | 7 | 1998 | 23711 | 0.030 |
Why?
|
| DNA Primers | 1 | 1997 | 2819 | 0.030 |
Why?
|
| Child, Preschool | 5 | 2018 | 42063 | 0.030 |
Why?
|
| U937 Cells | 1 | 2012 | 262 | 0.030 |
Why?
|
| Enzyme Inhibitors | 2 | 2001 | 3726 | 0.030 |
Why?
|
| Dermatitis Herpetiformis | 1 | 2012 | 24 | 0.030 |
Why?
|
| Multiple Trauma | 1 | 2015 | 369 | 0.030 |
Why?
|
| Organ Culture Techniques | 1 | 2014 | 796 | 0.030 |
Why?
|
| Immunization, Passive | 1 | 2014 | 616 | 0.030 |
Why?
|
| Cooking | 1 | 2014 | 311 | 0.030 |
Why?
|
| Biological Assay | 1 | 2015 | 630 | 0.020 |
Why?
|
| Acetamides | 1 | 2013 | 256 | 0.020 |
Why?
|
| Intestinal Secretions | 1 | 1991 | 15 | 0.020 |
Why?
|
| Fluoroquinolones | 1 | 2013 | 308 | 0.020 |
Why?
|
| Comorbidity | 1 | 2006 | 10551 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2012 | 915 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2018 | 1791 | 0.020 |
Why?
|
| Interleukin-17 | 1 | 2017 | 910 | 0.020 |
Why?
|
| Enema | 1 | 2011 | 141 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2015 | 630 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2013 | 12293 | 0.020 |
Why?
|
| Skin Diseases | 1 | 2020 | 1089 | 0.020 |
Why?
|
| Receptors, Fc | 1 | 2014 | 534 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2010 | 7818 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 1997 | 6538 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 1997 | 2061 | 0.020 |
Why?
|
| Autoimmunity | 1 | 2018 | 1370 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 1997 | 18957 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2007 | 16939 | 0.020 |
Why?
|
| Cell Death | 1 | 1996 | 1672 | 0.020 |
Why?
|
| Vaccination | 2 | 2018 | 3361 | 0.020 |
Why?
|
| Weight Gain | 2 | 2012 | 2347 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2015 | 1697 | 0.020 |
Why?
|
| Brunner Glands | 1 | 1989 | 11 | 0.020 |
Why?
|
| Kinetics | 1 | 1997 | 6377 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 1997 | 2105 | 0.020 |
Why?
|
| Massachusetts | 2 | 2013 | 8803 | 0.020 |
Why?
|
| Intention | 1 | 2012 | 345 | 0.020 |
Why?
|
| Duodenitis | 1 | 2009 | 20 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2015 | 857 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2016 | 2362 | 0.020 |
Why?
|
| Drug Costs | 1 | 1998 | 1185 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2015 | 3084 | 0.020 |
Why?
|
| Obesity | 1 | 2012 | 12922 | 0.020 |
Why?
|
| Ireland | 2 | 1987 | 172 | 0.020 |
Why?
|
| Food | 1 | 2014 | 771 | 0.020 |
Why?
|
| Fluoresceins | 1 | 2009 | 234 | 0.020 |
Why?
|
| Apoptosis | 2 | 2017 | 9501 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2020 | 1647 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2009 | 24123 | 0.020 |
Why?
|
| Epitopes | 1 | 2015 | 2503 | 0.020 |
Why?
|
| Fatigue | 1 | 2016 | 1544 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2018 | 1977 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2017 | 3157 | 0.020 |
Why?
|
| Viscosity | 1 | 2009 | 335 | 0.020 |
Why?
|
| Asymptomatic Diseases | 1 | 2012 | 587 | 0.020 |
Why?
|
| Dehydration | 1 | 2010 | 216 | 0.020 |
Why?
|
| Diet Surveys | 1 | 2012 | 1161 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 1997 | 2907 | 0.020 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2012 | 581 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2013 | 13262 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2012 | 2753 | 0.020 |
Why?
|
| Rheology | 1 | 2009 | 348 | 0.020 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2009 | 305 | 0.020 |
Why?
|
| Boston | 1 | 2021 | 9280 | 0.020 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2014 | 1355 | 0.020 |
Why?
|
| Chemokine CXCL2 | 2 | 1998 | 108 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 1994 | 3094 | 0.020 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2011 | 326 | 0.020 |
Why?
|
| Complement Activation | 1 | 1989 | 446 | 0.020 |
Why?
|
| Toxoids | 1 | 2007 | 11 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2000 | 9716 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 4713 | 0.020 |
Why?
|
| Elasticity | 1 | 2009 | 652 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2017 | 3215 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2013 | 1949 | 0.020 |
Why?
|
| Urea | 1 | 2009 | 446 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2015 | 1974 | 0.020 |
Why?
|
| Gastroesophageal Reflux | 1 | 2014 | 816 | 0.020 |
Why?
|
| Adoptive Transfer | 1 | 2009 | 822 | 0.020 |
Why?
|
| Appointments and Schedules | 1 | 2010 | 442 | 0.020 |
Why?
|
| Educational Status | 1 | 2014 | 2515 | 0.020 |
Why?
|
| Endoscopes, Gastrointestinal | 1 | 2006 | 45 | 0.020 |
Why?
|
| Seasons | 1 | 2012 | 1522 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 20509 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 6544 | 0.020 |
Why?
|
| Miniaturization | 1 | 2006 | 153 | 0.020 |
Why?
|
| Wound Healing | 1 | 2017 | 2788 | 0.020 |
Why?
|
| Mitochondria | 1 | 1999 | 3600 | 0.020 |
Why?
|
| Income | 1 | 2014 | 1875 | 0.020 |
Why?
|
| Fibroblasts | 1 | 1996 | 4090 | 0.020 |
Why?
|
| Parenteral Nutrition | 1 | 2010 | 656 | 0.020 |
Why?
|
| Macrophages | 2 | 1997 | 5745 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2012 | 2659 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2009 | 1975 | 0.020 |
Why?
|
| Administration, Cutaneous | 1 | 2007 | 713 | 0.020 |
Why?
|
| Reference Values | 1 | 2012 | 4925 | 0.010 |
Why?
|
| Th1 Cells | 1 | 2009 | 1032 | 0.010 |
Why?
|
| Health Surveys | 1 | 2014 | 4063 | 0.010 |
Why?
|
| Patient Readmission | 1 | 2018 | 3323 | 0.010 |
Why?
|
| Gastrointestinal Tract | 1 | 2010 | 830 | 0.010 |
Why?
|
| Education, Medical, Continuing | 1 | 2009 | 830 | 0.010 |
Why?
|
| Mucous Membrane | 1 | 2007 | 657 | 0.010 |
Why?
|
| Inflammation Mediators | 1 | 2012 | 1881 | 0.010 |
Why?
|
| Antigens, CD | 1 | 1994 | 4000 | 0.010 |
Why?
|
| HEK293 Cells | 1 | 2012 | 4264 | 0.010 |
Why?
|
| Administration, Rectal | 1 | 2002 | 70 | 0.010 |
Why?
|
| HLA Antigens | 1 | 1988 | 1368 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2015 | 9530 | 0.010 |
Why?
|
| Motivation | 1 | 2012 | 1993 | 0.010 |
Why?
|
| Alleles | 1 | 2014 | 6898 | 0.010 |
Why?
|
| Mannitol | 2 | 1993 | 180 | 0.010 |
Why?
|
| Cell Movement | 1 | 1994 | 5206 | 0.010 |
Why?
|
| Mutation | 2 | 2004 | 29932 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2010 | 36290 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2009 | 2651 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 2014 | 2471 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 12531 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2012 | 2315 | 0.010 |
Why?
|
| Lac Operon | 1 | 2001 | 237 | 0.010 |
Why?
|
| Acute Disease | 1 | 2012 | 7269 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 7806 | 0.010 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2009 | 1810 | 0.010 |
Why?
|
| Transfection | 2 | 2001 | 5781 | 0.010 |
Why?
|
| Video Recording | 1 | 2006 | 955 | 0.010 |
Why?
|
| Toll-Like Receptors | 1 | 2004 | 590 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2013 | 10182 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 3986 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2008 | 2668 | 0.010 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2006 | 786 | 0.010 |
Why?
|
| Internet | 1 | 2012 | 3078 | 0.010 |
Why?
|
| Helicobacter | 1 | 2000 | 111 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 2009 | 2299 | 0.010 |
Why?
|
| Receptors, Lymphocyte Homing | 1 | 2000 | 141 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2001 | 869 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 5397 | 0.010 |
Why?
|
| Mental Disorders | 1 | 2020 | 6796 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1988 | 2536 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2009 | 2634 | 0.010 |
Why?
|
| Swine | 1 | 2009 | 5899 | 0.010 |
Why?
|
| Retroviridae | 1 | 2001 | 850 | 0.010 |
Why?
|
| Delayed-Action Preparations | 1 | 2002 | 961 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 2001 | 863 | 0.010 |
Why?
|
| Communication | 1 | 2012 | 3849 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2013 | 6381 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2001 | 1991 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 11152 | 0.010 |
Why?
|
| Safety | 1 | 2002 | 1148 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 20080 | 0.010 |
Why?
|
| Chymases | 1 | 1997 | 73 | 0.010 |
Why?
|
| Mast Cells | 2 | 1996 | 1390 | 0.010 |
Why?
|
| Heterozygote | 1 | 2004 | 2798 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2002 | 2852 | 0.010 |
Why?
|
| Plasmids | 1 | 2001 | 2275 | 0.010 |
Why?
|
| ras Proteins | 1 | 2001 | 1052 | 0.010 |
Why?
|
| Models, Biological | 1 | 2012 | 9467 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 1993 | 7850 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2001 | 4169 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2009 | 8555 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 25942 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2014 | 5889 | 0.010 |
Why?
|
| Lumbosacral Region | 1 | 1997 | 291 | 0.010 |
Why?
|
| Guinea Pigs | 1 | 1996 | 1316 | 0.010 |
Why?
|
| Ligands | 1 | 2001 | 3276 | 0.010 |
Why?
|
| Metalloendopeptidases | 1 | 1996 | 393 | 0.010 |
Why?
|
| Lectins | 1 | 1996 | 484 | 0.010 |
Why?
|
| Macrophage Activation | 1 | 1997 | 554 | 0.010 |
Why?
|
| Hypertension | 1 | 2014 | 8594 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2002 | 6238 | 0.010 |
Why?
|
| SRS-A | 1 | 1993 | 132 | 0.010 |
Why?
|
| CHO Cells | 1 | 1996 | 1389 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 3707 | 0.010 |
Why?
|
| Platelet Activating Factor | 1 | 1993 | 143 | 0.010 |
Why?
|
| Dinoprostone | 1 | 1996 | 598 | 0.010 |
Why?
|
| Tritium | 1 | 1993 | 707 | 0.010 |
Why?
|
| Leukotriene B4 | 1 | 1993 | 280 | 0.010 |
Why?
|
| Serine Endopeptidases | 1 | 1997 | 1021 | 0.010 |
Why?
|
| Biphenyl Compounds | 1 | 1997 | 992 | 0.010 |
Why?
|
| Chromatography, Affinity | 1 | 1993 | 534 | 0.010 |
Why?
|
| Liver | 1 | 1987 | 7509 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1993 | 2186 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1993 | 1744 | 0.010 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 1993 | 663 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2002 | 4219 | 0.010 |
Why?
|
| Mass Screening | 1 | 2006 | 5423 | 0.010 |
Why?
|
| Heart Failure | 1 | 2014 | 11847 | 0.010 |
Why?
|
| Complement Membrane Attack Complex | 1 | 1989 | 105 | 0.010 |
Why?
|
| Calcium | 1 | 2001 | 5725 | 0.000 |
Why?
|
| Immunoglobulins | 1 | 1991 | 859 | 0.000 |
Why?
|
| Complement C3 | 1 | 1989 | 451 | 0.000 |
Why?
|
| DNA | 1 | 2001 | 7233 | 0.000 |
Why?
|
| Antigens | 1 | 1989 | 1447 | 0.000 |
Why?
|
| Lymphocyte Activation | 1 | 1988 | 5496 | 0.000 |
Why?
|
| Chronic Disease | 1 | 1991 | 9287 | 0.000 |
Why?
|
| B-Lymphocytes | 1 | 1988 | 4742 | 0.000 |
Why?
|